0QLR - Ticker AI Digest

Novartis AG 📰 3
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (0QLR) 3
0QLR 20:01
Novartis AG
Novartis successfully completes acquisition of AveXis, Inc.
0QLR 05:16
Novartis AG
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
0QLR 04:46
Novartis AG
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
AI 0
No items for this category on selected date.
Acquisitions 2
0QLR 20:01
Novartis AG
Novartis successfully completes acquisition of AveXis, Inc.
0QLR 05:01
Novartis AG
Novartis provides update on proposed acquisition of AveXis
Agreement 1
0QLR 20:02
Novartis AG
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
Approvals 3
0QLR 22:25
Novartis AG
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
0QLR 20:27
Novartis AG
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
0QLR 20:11
Novartis AG
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
0QLR 20:06
Novartis AG
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 1
0QLR 05:16
Novartis AG
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 2
0QLR 04:46
Novartis AG
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
0QLR 05:01
Novartis AG
Novartis tender offer for AveXis commences
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 19
0QLR 20:01
Novartis AG
Novartis successfully completes acquisition of AveXis, Inc.
0QLR 05:16
Novartis AG
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)
0QLR 04:46
Novartis AG
Novartis completes tender offer for all outstanding shares of AveXis, Inc.
0QLR 22:25
Novartis AG
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
0QLR 05:16
Novartis AG
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
0QLR 20:06
Novartis AG
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
0QLR 20:27
Novartis AG
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
0QLR 05:01
Novartis AG
Novartis provides update on proposed acquisition of AveXis
0QLR 20:11
Novartis AG
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
0QLR 20:06
Novartis AG
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
0QLR 05:16
Novartis AG
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
0QLR 05:16
Novartis AG
New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients
0QLR 05:16
Novartis AG
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
0QLR 05:01
Novartis AG
Novartis delivered a strong first quarter and acted to become a more focused medicines company
0QLR 20:02
Novartis AG
Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders
0QLR 20:01
Novartis AG
Novartis presents first-of-its-kind evidence at AAN reinforcing robust and consistent efficacy of AimovigTM* (erenumab) for migraine patients with multiple treatment failures
0QLR 05:16
Novartis AG
Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
0QLR 05:01
Novartis AG
Novartis tender offer for AveXis commences
0QLR 05:16
Novartis AG
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes

AI Crunch

Single-Ticker AI Crunch
0QLR signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Novartis AG. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full 0QLR AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for 0QLR on 2018-05-15.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
195431300000
Enterprise Value
-
Public Float
-
Broker Target
-
Shares Out
-
Long Interest
60
Short Interest
40
Exchange
LSE
Currency Code
GBP
ISIN
CH0012005267
Market
None
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-02-04
Net Debt
-
Cash
-
EPS
-
Net Income
-
Revenue
-
Enterprise Value
-
Trailing PE
-
Forward PE
-
Price Sales TTM
-
Price Book MRQ
-
EV Revenue
-
EV EBITDA
-

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
-
Institutions As Of
-
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
0
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

3 live catalysts just hit 0QLR.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2018-05-15 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
3 Today
Catalyst Pulse
Novartis AG has fresh news flow feeding the chart narrative.
20:01 Today's Catalyst Novartis successfully completes acquisition of AveXis, Inc. 05:16 Today's Catalyst Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*) 04:46 Today's Catalyst Novartis completes tender offer for all outstanding shares of AveXis, Inc.
AI Charts Studio
0QLR Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2018-05-15 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast